Companies › Actinogen Medical
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Xanamem 11β-hydroxysteroid dehydrogenase type 1 inhibitor | CYP11B1 | Phase 2 | Dementia Moderate | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06125951 | Xanamem | Phase 2 | Dementia Moderate | Neurology | Feb 2028 |
Aptinyx Neuron23 Bial R&D Investments SHINKEI Therapeutics NeuroTherapia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.